This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Neuralstem Closes $20 Million Registered Direct Offering

Stock quotes in this article: CUR









ROCKVILLE, Md., Jan. 9, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced today that on January 8, 2014, it closed on a $20 million investment from leading institutional and accredited investors in a registered direct placement (the "Offering") of 6,872,859 shares of common stock at a price of $2.91 per share. In addition, the Company issued to the investors in the Offering warrants to purchase common stock equal to one-half of the number of shares purchased by the investors in the Offering, for a total of 3,436,435 shares. The warrants have an exercise price of $3.64 per share and are exercisable from the issuance date for a period of five years, and upon exercise would result in additional proceeds to the Company of approximately $12.5 million. The Company intends to use the proceeds from this Offering to fund its on-going clinical trials, and for working capital and general corporate purposes.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

"We are very pleased to have raised the capital in this Offering from leading institutional investors, including dedicated institutional healthcare investors. With the proceeds strengthening our cash balance, we have the resources to further advance our cell therapy and small molecule clinical trial programs," said Richard Garr, President and Chief Executive Officer of Neuralstem. "Our lead cell therapy product candidate, NSI-566, is a spinal cord-derived stem cell therapy candidate that is in Phase II clinical trials for amyotrophic lateral sclerosis (ALS). In addition to ALS, we are targeting major central nervous system conditions with the NSI-566 cell therapy platform, including spinal cord injury and ischemic stroke. The Company expects to commence an FDA-approved Phase I safety trial in chronic spinal cord injury during the first quarter of 2014. In addition, we have recently completed a Phase Ib safety and tolerability trial for NSI-189, our small molecule product candidate for the treatment of major depressive disorder (MDD). Our medical and scientific teams are currently reviewing the data."

T.R. Winston & Company, LLC acted as the exclusive placement agent for the Offering.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,823.88 -219.02 -1.29%
S&P 500 1,949.80 -22.49 -1.14%
NASDAQ 4,428.10 -65.29 -1.45%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs